Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders.
Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
The company's preclinical stage product candidates also include AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain.
Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 25 | 12.50 Increased by +420.51% | -6.75 Increased by +285.19% |
| Nov 12, 24 | -10.75 Decreased by -2.01 K% | -13.50 Increased by +20.37% |
| Aug 13, 24 | -43.75 Decreased by -16.10 K% | -38.25 Decreased by -14.38% |
| May 13, 24 | -2.75 Decreased by -2.02 K% | - |
| Mar 26, 24 | -3.90 Decreased by -1.40 K% | -2.70 Decreased by -44.44% |
| Nov 15, 23 | -0.51 Increased by +21.54% | -0.26 Decreased by -96.15% |
| Aug 14, 23 | -0.27 Increased by +46.00% | -0.16 Decreased by -68.75% |
| May 12, 23 | -0.13 Increased by +70.45% | -0.30 Increased by +56.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.39 M Increased by +25.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.01 M Increased by +66.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -3.45 M Decreased by -10.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.22 M Decreased by -131.68% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -4.56 M Decreased by -58.83% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.99 M Increased by +20.80% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.11 M Increased by +46.93% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.39 M Increased by +73.01% | Decreased by N/A% Decreased by N/A% |